For example, the downregulation of BCL-2 reflects the loss of addiction to this protein, but the compensatory upregulation of the anti-apoptotic proteins not targeted by venetoclax (BCL-XL and MCL1) is observed in leukemia or cancer cell line venetoclax-treated cells [168]. The gene discussed is BCL2; the disease is cancer.